Dupixent For Moderate-To-Severe Asthma Treatment Market Expected To Reach ~$8.1 Billion By 2032. December 13, 2025 7:27 am - The Dupixent market for moderate-to-severe asthma is valued at $3.25 ...
Sanofi’s latest fair value estimate has been nudged down from €106.26 to €105.20 as analysts factor in slightly softer revenue growth assumptions, even as the company’s overall risk profile remains ...
A secretive biotechnology-centered hedge fund bought shares of Kymera Therapeutics after the stock soared to its highest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback